Skip to main content

Table 2 Incidence of nausea and vomiting among breast cancer patients after receiving different chemotherapy regimens (%)

From: Relationship between traditional Chinese medicine constitutional types with chemotherapy-induced nausea and vomiting in patients with breast cancer: an observational study

Regimens

n (n = 612)

CINV [n (%)]

Grade 0-II (n = 339)

Grade III-IV (n = 273)

CAF

59

36 (61.0)

23 (39.0)

CEF

107

59 (55.1)

48 (44.9)

TEC

57

29 (50.9)

28 (49.1)

TE

122

74 (60.7)

48 (39.3)

TAC

61

40 (65.6)

21 (34.4)

TA

51

24 (47.1)

27 (52.9)

AC

40

21 (52.5)

19 (47.5)

EC

115

56 (48.7)

59 (51.3)

  1. Comparison between groups showed that the incidence of nausea and vomiting between the different chemotherapy groups was not statistically significant (chi-square test, P = 0.342)
  2. CINV chemotherapy-induced nausea and vomiting, CAF cyclophosphamide, adriamycin, fluorouracil, CEF cyclophosphamide, epirubicin, and fluorouracil, AC adriamycin and cyclophosphamide, EC epirubicin and fluorouracil, TAC docetaxel, adriamycin, and cyclophosphamide, TEC docetaxel, epirubicin, and cyclophosphamide, TA pacilitaxel and adriamycin, TE docetaxel and epirubicin